About this Medicine article
COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers by Paul Rodrigues; Harun Bangali; Ahmad Hammoud; Yasser Fakri Mustafa; Hussein Riyadh Abdul Kareem Al-Hetty; Adnan Taan Alkhafaji; Maha Medha Deorari; Muataz Mohammed Al-Taee; Rahman S. Zabibah; Ali Alsalamy is a Medicine article available to read on EtoBox.
Cyclooxygenase (COX) enzymes are pivotal in inflammation and cancer development. COX-2, in particular, has been implicated in tumor growth, angiogenesis, and immune evasion. Recently, COX-2 inhibitors have arisen as potential therapeutic agents in cancer treatment. In addition, combining COX inhibitors with other treatment modalities has demonstrated the potential to improve therapeutic efficacy. This review aims to investigate the effects of COX inhibition, both alone and in combination with other methods, on signaling pathways and carcinogenesis in various cancers. In this study, a literature search of all major academic databases was conducted (PubMed, Scholar google), including the leading research on the mechanisms of COX-2, COX-2 inhibitors, monotherapy with COX-2 inhibitors, and combining COX-2-inhibitors with chemotherapeutic agents in tumors. The study encompasses preclinical and clinical evidence, highlighting the positive findings and the potential implications for clinical practice. According to preclinical studies, multiple signaling pathways implicated in tumor cell proliferation, survival, invasion, and metastasis can be suppressed by inhibiting COX. In addition, com
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Paul Rodrigues; Harun Bangali; Ahmad Hammoud; Yasser Fakri Mustafa; Hussein Riyadh Abdul Kareem Al-Hetty; Adnan Taan Alkhafaji; Maha Medha Deorari; Muataz Mohammed Al-Taee; Rahman S. Zabibah; Ali Alsalamy
- Publisher
- Springer Science and Business Media LLC
- Published
- 2024
- Language
- EN
- Field
- Medicine (Health Sciences)